OTCMKTS:OTLC Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis $0.04 +0.00 (+3.97%) As of 06/26/2026 01:07 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsBuy This Stock About Oncotelic Therapeutics Stock (OTCMKTS:OTLC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oncotelic Therapeutics alerts:Sign Up Key Stats Today's Range$0.04▼$0.0550-Day Range$0.04▼$0.0652-Week Range$0.02▼$0.11Volume60,948 shsAverage Volume222,082 shsMarket Capitalization$20.27 millionP/E Ratio0.08Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity. Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs. The company has conducted early‐phase clinical studies in solid tumors and is exploring combination strategies with immune checkpoint inhibitors. Oncotelic’s research and development efforts are focused on expanding the potential of its oncolytic platform across multiple cancer indications and optimizing its diagnostic capabilities to support personalized treatment strategies. Headquartered in Gaithersburg, Maryland, Oncotelic operates with a lean scientific and management team. Leadership is spearheaded by President and Chief Executive Officer Bryan M. Saltjian, Ph.D., who brings extensive experience in viral immunotherapy and biotechnology commercialization. Under his guidance, Oncotelic aims to advance its pipeline through clinical milestones and strategic partnerships that can bring its oncolytic and diagnostic innovations to the broader oncology community.AI Generated. May Contain Errors. Read More Receive OTLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OTLC Stock News HeadlinesOncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026June 18, 2026 | globenewswire.comOncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing ServicesJune 17, 2026 | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.June 27 at 1:00 AM | Banyan Hill Publishing (Ad)Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 KeynoteJune 8, 2026 | markets.businessinsider.comNetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery TechnologiesJune 5, 2026 | globenewswire.comOncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology TherapiesJune 4, 2026 | globenewswire.comSapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b ProgramJune 3, 2026 | globenewswire.comOncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical InfrastructureJune 2, 2026 | globenewswire.comSee More Headlines OTLC Stock Analysis - Frequently Asked Questions How have OTLC shares performed this year? Oncotelic Therapeutics' stock was trading at $0.0775 at the start of the year. Since then, OTLC stock has decreased by 42.6% and is now trading at $0.0445. How were Oncotelic Therapeutics' earnings last quarter? Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) released its quarterly earnings data on Wednesday, April, 15th. The company reported $0.59 earnings per share for the quarter. How do I buy shares of Oncotelic Therapeutics? Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncotelic Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncotelic Therapeutics investors own include MariMed (MRMD), DSS (DSS), Cemex (CX), CohBar (CWBR), Company Calendar Last Earnings4/15/2026Today6/27/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:OTLC CIK908259 Webwww.mateon.com Phone(650) 635-7000Fax650-635-7001Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.59 Trailing P/E Ratio0.08 Forward P/E RatioN/A P/E GrowthN/ANet Income$249.28 million Net MarginsN/A Pretax MarginN/A Return on Equity183.45% Return on Assets117.54% Debt Debt-to-Equity Ratio0.01 Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual Sales$70 thousand Price / Sales289.56 Cash Flow$0.56 per share Price / Cash Flow0.08 Book Value$0.59 per share Price / Book0.08Miscellaneous Outstanding Shares455,490,000Free Float276,849,000Market Cap$20.27 million OptionableNot Optionable Beta-0.34 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:OTLC) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncotelic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncotelic Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
